header logo image


Page 651«..1020..650651652653..660670..»

The 60-year recruitment crisis | Article – Pulse

March 6th, 2020 11:44 pm

It probably feels as though recruitment is worse now than it ever was.

But, general practice being what it is, there have been plenty of recruitment crises through the ages. (And don't forget to click on the pictures to expand!)

recruitment birthday 1961 05 fp 781x1000px

This 1961 piece says the first decade of the NHS (1948-1958) was characterised by a surplus of doctors, but this situation is in the process of being reversed.

recruitment birthday 1961 09 practice applicants 804x1000px

Later in the year, the Dissector suggests that the number of vacancies in the BMJ show that, as he puts it (it was always he in 1960s Pulse), Practice applicants are below demand.

recruitment birthday 1962 12 front page 828x1000px

There were plus sides to this, of course as we pointed out the following year, GPs scarcity put them in a strong position.

recruitment birthday 1970 10 fp 707x1000px

Fast forward a few years and we report in 1970 on GP manpower in low gear, leading to a growing reliance on foreign doctors. Of course, this is nothing like these days back then, the NHS could actually attract overseas doctors.

recruitment birthday 1981 10 fp 701x1000px

Things are still not getting any better in 1981. More GPs are needed, said a report from MPs. This is especially so because of the move for GPs to help with the hospital service, and preventative medicine. This is a great help to the current Pulse team, of course, because if reporters ever miss a deadline, they can just submit this story. Again. And again.

recruitment birthday 1982 04 record increase 957x1000px

But, a mere year later, it looks like things were picking up. It revealed that in 1981, there had been success in attracting record numbers 826 in all (Messrs Hunt and Hancock look wistfully on).

recruitment birthday 1982 04 gp sends 400 letters 873x1000px

However, there are always losers in these scenarios. Spare a moment for Dr Parat Jit Singh who, in the same month, was featured on the front page of Pulse because of his 400 job applications with no success. (Dr Jit Singh if you are reading this, please get in touch, as we know of a few thousand practices looking for a GP now).

recruitment birthday 1990 09 right hand page 712x1000px

At the start of the 1990s, things were glowing in GP land, and it wasnt just the lava lamps and glowsticks. A report showed that the number of patients per GP was 12% lower than a decade earlier.

recruitment birthday 1992 05 poor pay 695x1000px

But, as seems to increasingly be the case, two years later and we see that a recruitment crisis is looming in general practice. Trainee numbers are down due to poor pay and the increasing business ethics involved in general practice. Interestingly, the former trainee representative to the RCGP is quoted a Dr Sarah Jarvis, who later became one of the most prominent media doctors around.

recruitment birthday 1995 11 gp recruitment crisis 707x1000px

And so it came to pass. In 1995, the crisis showed no sign of abatement.

recruitment birthday 1998 11 bma hits right note 1000x667px

An editorial three years later rightly points out that focusing on the recruitment crisis is probably a better way for the BMA to be successful in increasing pay and probably not before time either.

recruitment birthday 1995 10 more eu doctors 1000x884px

Thats not to say there were not solutions. One, which seemed eminently sensible, was to recruit more EU doctors. Maybe we can think about that now?

recruitment birthday 2009 10 fp 715x1000px

And another involved incentives for partnerships. Though that will probably never catch on.

Visit link:
The 60-year recruitment crisis | Article - Pulse

Read More...

European Medicines Agency taking action to accelerate development of medical products to treat and coronavirus – The Parliament Magazine

March 6th, 2020 5:49 am

Photocredit: Press Association

Guido Rasi, the European Medicines Agency's executive director, said the EMA has activated its plan for managing emerging health threats.

Rasi added, "The new coronavirus has been declared a public health emergency of international concern by the World Health Organization, and we are drawing on the strong expertise of the European medicines network to provide fast-track scientific advice and give prompt feedback on any proposed medicine developments.

The EMA, now based in Amsterdam, says it is collaborating and exchanging information with EU public health authorities and the commission.

RELATED CONTENT

An agency spokesman said, There are currently no commercially available medicinal products that are authorised to detect, treat or prevent infections with the virus. The EMA is ready to support medicine developers with all available regulatory tools to advance and expedite the development of effective measures to fight and prevent the spread of this virus.

This is a new strain of coronavirus that has not been previously seen in humans. Although the most likely primary source of this outbreak is of animal origin, human-to-human transmission has been confirmed and investigations are ongoing to determine all sources. Cases have now been detected in several countries in Asia, Australia, Europe and North America.

Further global spread is likely.

Reports of medicines shortages are increasingly prevalent in Europe, warned, Christoph Stoller, President of Medicines for Europe, which represents the generic, biosimilar and value-added medicines industries across Europe.

He said, Ensuring the availability of essential medicines should be an EU priority. The EU should tackle the economic and regulatory root causes of shortages and establish a pan-European mechanism to coordinate EU and national policies to reduce the risk of shortages and to avoid spill over effects through which one countrys policy would create supply issues in another.

"There are currently no commercially available medicinal products that are authorised to detect, treat or prevent infections with the virus. The EMA is ready to support medicine developers with all available regulatory tools to advance and expedite the development of effective measures to fight and prevent the spread of this virus"European Medicines Agencyspokesman

He added, Preventing supply issues becomes especially pertinent considering the ongoing COVID-19 coronavirus outbreak globally.

Meanwhile, the EMA, which was based in London but had to relocate because of Brexit, has insisted there is no risk to the supply of medicines due to the UKs EU exit during the transition period.

In a bid to allay fears that the supply of medicines could be adversely affected, the agency has reassured consumers and businesses alike but also warned of legal repercussions when the transition period ends.

An EMA spokesman said that during the transition period until December 31 2020, EU pharmaceutical law will continue to apply to the UK meaning that until the end of the transition period pharmaceutical companies can continue to carry out activities in the UK and supply their medicines as before.

Continue reading here:
European Medicines Agency taking action to accelerate development of medical products to treat and coronavirus - The Parliament Magazine

Read More...

UConn Researchers Discover New Stem Cells That Can Generate New Bone – UConn Today

March 6th, 2020 5:47 am

A population of stem cells with the ability to generate new bone has been newly discovered by a group of researchers at the UConn School of Dental Medicine.

In the journal STEM CELLS, lead investigator Dr. Ivo Kalajzic, professor of reconstructive sciences, postdoctoral fellows Dr. Sierra Root and Dr. Natalie Wee, and collaborators at Harvard, Maine Medical Research Center, and the University of Auckland present a new population of cells that reside along the vascular channels that stretch across the bone and connect the inner and outer parts of the bone.

This is a new discovery of perivascular cells residing within the bone itself that can generate new bone forming cells, said Kalajzic. These cells likely regulate bone formation or participate in bone mass maintenance and repair.

Stem cells for bone have long been thought to be present within bone marrow and the outer surface of bone, serving as reserve cells that constantly generate new bone or participate in bone repair. Recent studies have described the existence of a network of vascular channels that helped distribute blood cells out of the bone marrow, but no research has proved the existence of cells within these channels that have the ability to form new bones.

In this study, Kalajzic and his team are the first to report the existence of these progenitor cells within cortical bone that can generate new bone-forming cells osteoblasts that can be used to help remodel a bone.

To reach this conclusion, the researchers observed the stem cells within an ex vivo bone transplantation model. These cells migrated out of the transplant, and began to reconstruct the bone marrow cavity and form new bone.

While this study shows there is a population of cells that can help aid bone formation, more research needs to be done to determine the cells potential to regulate bone formation and resorption.

This study was funded by the Regenerative Medicine Research Fund (RMRF; 16-RMB-UCHC-10) by CT Innovations and by National Institute of Arthritis and Musculoskeletal and Skin.

Read this article:
UConn Researchers Discover New Stem Cells That Can Generate New Bone - UConn Today

Read More...

Doctors altered a patient’s DNA to treat blindness with controversial gene editing tool – USA TODAY

March 6th, 2020 5:47 am

Marilynn Marchione, AP Chief Medical Writer Published 7:35 a.m. ET March 4, 2020 | Updated 1:46 p.m. ET March 4, 2020

Curious about your dog's family history, genes and medical risks? New DNA testing kits for pups will give you those answers. USA TODAY

Scientists say they have used the gene editing tool CRISPR inside someone's body for the first time, a new frontier for efforts to operate on DNA, the chemical code of life, to treat diseases.

A patient recently had it done at the Casey Eye Institute at Oregon Health & Science University in Portland for an inherited form of blindness, the companies that make the treatment announced Wednesday. They would not give details on the patient or when the surgery occurred.

It may take up to a month to see if it worked to restore vision. If the first few attempts seem safe, doctors plan to test it on 18 children and adults.

We literally have the potential to take people who are essentially blind and make them see, said Charles Albright, chief scientific officer at Editas Medicine, the Cambridge, Massachusetts-based company developing the treatment with Dublin-based Allergan. We think it could open up a whole new set of medicines to go in and change your DNA.

Charles Albright, executive vice president and chief scientific officer at Editas Medicine, a genome-editing company, in Cambridge, Mass., walks through the company's office on Jan. 8, 2020.(Photo: Rodrique Ngowi, AP)

Dr. Jason Comander, an eye surgeon at Massachusetts Eye and Ear in Boston, another hospital that plans to enroll patients in the study, said it marks a new era in medicine using a technology that makes editing DNA much easier and much more effective.

Doctors first tried in-the-body gene editing in 2017 for a different inherited disease using a tool called zinc fingers. Many scientists believe CRISPR is a much easier tool for locating and cutting DNA at a specific spot, so interest in the new research is very high.

The people in this study have Leber congenital amaurosis, caused by a gene mutation that keeps the body from making a protein needed to convert light into signals to the brain, which enables sight. They're often born with little vision and can lose even that within a few years.

Scientists can't treat it with standard gene therapy supplying a replacement gene because the one needed is too big to fit inside the disabled viruses that are used to ferry it into cells.

So they're aiming to edit, or delete the mutation by making two cuts on either side of it. The hope is that the ends of DNA will reconnect and allow the gene to work as it should.

It's done in an hourlong surgery under general anesthesia. Through a tube the width of a hair, doctors drip three drops of fluid containing the gene editing machinery just beneath the retina, the lining at the back of the eye that contains the light-sensing cells.

Avoid anxiety: How should you talk to your children about coronavirus

'Landmark study': More than 100 genes tied to autism identified in large study

"Once the cell is edited, its permanent and that cell will persist hopefully for the life of the patient," because these cells don't divide, said one study leader not involved in this first case, Dr. Eric Pierce at Massachusetts Eye and Ear.

Doctors think they need to fix a 10th to a third of the cells to restore vision. In animal tests, scientists were able to correct half of the cells with the treatment, Albright said.

The eye surgery itself poses little risk, doctors say. Infections and bleeding are relatively rare complications.

One of the biggest potential risks from gene editing is that CRISPR could make unintended changes in other genes, but the companies have done a lot to minimize that and to ensure that the treatment cuts only where it's intended to, Pierce said. He has consulted for Editas and helped test a gene therapy, Luxturna, that's sold for a different type of inherited blindness.

Some independent experts were optimistic about the new study.

The gene editing approach is really exciting. We need technology that will be able to deal with problems like these large genes, said Dr. Jean Bennett, a University of Pennsylvania researcher who helped test Luxturna at the Childrens Hospital of Philadelphia.

In one day, she had three calls from families seeking solutions to inherited blindness.

Its a terrible disease," she said. "Right now they have nothing.

Dr. Kiran Musunuru, another gene editing expert at the University of Pennsylvania, said the treatment seems likely to work, based on tests in human tissue, mice and monkeys.

The gene editing tool stays in the eye and does not travel to other parts of the body, so "if something goes wrong, the chance of harm is very small," he said. "It makes for a good first step for doing gene editing in the body.

Although the new study is the first to use CRISPR to edit a gene inside the body, another company, Sangamo Therapeutics, has been testing zinc finger gene editing to treat metabolic diseases.

Other scientists are using CRISPR to edit cells outside the body to try to treat cancer, sickle cell and some other diseases.

All of these studies have been done in the open, with government regulators' approval, unlike a Chinese scientist's work that brought international scorn in 2018. He Jiankui used CRISPR to edit embryos at the time of conception to try to make them resistant to infection with the AIDS virus. Changes to embryos' DNA can pass to future generations, unlike the work being done now in adults to treat diseases.

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2020/03/04/crispr-gene-editing-tool-used-inside-patient-blindness-portland/4950458002/

Visit link:
Doctors altered a patient's DNA to treat blindness with controversial gene editing tool - USA TODAY

Read More...

Scott Bowman: Part one: Embracing the Blindness of the Future – State-Journal.com

March 6th, 2020 5:47 am

The book of Ecclesiastes has a funny thing to say about the future and its one of those blindly obvious statements, that if youre in the right mood, seems extremely funny. It goes like this: Ecclesiastes 8:7 If no one knows what will happen, who can tell him when it will happen?

You may be thinking, "Well duh, of course thats true! But as you meditate on the future, we see that no one knows what will happen from one second to the next. The recent worldwide volatility of the disease, stock market, and life in general teach us that even if we knew the future, we couldnt handle all that life was throwing at us anyway.

So, I figure rather than trying to avoid the blindness of the future we experience, we should try to embrace it.

We just hatched our second batch of baby chicks on the farm last week. The first time we had two chicks, this time we had three. But one of them had big giant eyeballs, they were sticking out as if she had hyperthyroidism.

My kids called them googley-eyes and that eventually the name was shortened and we just called her: Google. It became apparent after a few days that Google was blind. I had to put the water bowl almost completely in front of her face so she could find the water.

But after a while, she figured out where the dish was. Google had to rely on her sense of feel and smell to find water.

It seems like seasons of blindness of the future are really about how God puts us into a place where reliance upon ourselves doesnt work and we must rely on God to help us see whats right in from to us.

The future is a place no one on earth has ever been before, only God in his divine omniscience can see whats there as he stands at the end beckoning us toward himself.

Maybe the best way to embrace the blindness of the future is to realize that we are weak and frail and need to learn to rely on God more than anything else in this life. The characters of the Bible certainly didnt have things all figured out, a quick survey of their lives reveal that they didnt have it all together, rather their lives are testimonies of complete reliance on God.

Ultimately, we have to realize that Gods strength and power are only made perfect in our weakness.

Everything around us in life seems to be happening at light speed. This often causes us to become very impatient. Technology, the stock market, food prices, electric cars, everything is changing around us very fast.

However, God works not at the speed of light, but at the speed of seed planted in the ground. If you expect to see anything happen in the future of your life or the Kingdom of God, then you had better be planting seed in the ground now or you will for certain have nothing in the future.

This is what I mean by embracing the blindness of the future, we learn to embrace that God moves at the speed of seed. Ultimately, embracing blindness to the future is to wrap our arms around the moment as we put seed in the ground and trust God that he will bring about the fruit he and we desire most.

Where we are blind to the future, God is already there, embracing God is then embracing the future.

See original here:
Scott Bowman: Part one: Embracing the Blindness of the Future - State-Journal.com

Read More...

Editas and Allergan Make Gene-Editing History With First Treatment of Blindness Drug – The Motley Fool

March 6th, 2020 5:46 am

Editas Medicine (NASDAQ:EDIT) and Allergan (NYSE:AGN) announced on Wednesday morning that they had just treated the first patient with Editas' flagship drug candidate EDIT-101 as part of the Brilliance phase 1/2 clinical trial. The new experimental gene-editing drug targets a rare eye disorder known as Leber congenital amaurosis (LCA).

What makes this particular treatment noteworthy is that it's the first time a patient's genes are being modified within the body, also known as anin vivotreatment.In comparison, most gene-editing drugs operate on an ex vivo basis, where targeted cells are removed from the patient first before they are modified and later returned. The trial will be testing 18 LCA patients to see how they respond to EDIT-101, which will be administered via a subretinal injection.

Image source: Getty Images.

"The first patient dosed in the BRILLIANCE clinical trial marks a significant milestone toward delivering on the promise and potential of CRISPR medicines to durably treat devastating diseases such as LCA10," said Cynthia Collins, CEO and president of Editas.

Leber congenital amaurosis is a type of blindness that first occurs in infants. Patients with the condition have mutations of specific genes responsible for the proper development of the retina, the part of the eye that detects light.

There's only one LCA treatment available right now, a pricey drug called Luxturna, which was developed by a now-bought-out biotech company calledSpark Therapeutics. However, the drug treats only a specific type of LCA, and it isn't available for most patients with the eye disorder.

Excerpt from:
Editas and Allergan Make Gene-Editing History With First Treatment of Blindness Drug - The Motley Fool

Read More...

Woman blames theft on distraction and partial blindness: Mayfield Heights Police Blotter – cleveland.com

March 6th, 2020 5:46 am

MAYFIELD HEIGHTS, Ohio

Theft: Mayfield Road

A Cleveland woman, 48, was charged with theft at Walmart Feb. 22 after she failed to ring $54 worth of merchandise at a self-checkout register. She explained that she was partially blind in one eye and was also distracted by a friend who was with her.

She was found to have an active felony warrant for grand theft out of Cuyahoga County and two misdemeanor warrants. She was subsequently taken to the county jail.

Theft: Golden Gate Plaza

A Cleveland woman, 36, was cited for theft at Marshalls Clothing Feb. 21 after trying to conceal a windbreaker jacket inside her clothing.

Lost property: Mayfield Ridge Road

An employee of an HVAC company reported Feb. 21 that he suspected his computer tablet had been stolen from his van or the front porch of a home. He had gone to the vacant home for work, but nobody was at the house. Officers were unable to determine where and when the tablet went missing.

Harassment: Mayfield Road

A Gates Mills Place resident reported Feb. 22 that she had received 21 phone calls in one day from a Cleveland woman, who threatened her and her child. She said her ex-boyfriend owes the woman money. Officers advised both women to have no further contact with each other.

Disturbance: SOM Center Road

Officers responded Feb. 23 to the Coppertree apartments for a report of four women fighting in a third-floor hallway. They learned that the incident began after an argument over the proper preparation of food.

The resident said one woman was his girlfriend and has anger issues. He asked that the Mayfield Heights woman, 21, leave the apartment, but she continued to be unruly and was subsequently charged with disorderly conduct.

Assault: Golden Gate Plaza

Two men got into fight behind the LaBarberia Institute of Hair Feb. 22 after one man confronted the other about derogatory social media posts he had made. The incident was not reported until Feb. 24, when surveillance video was reviewed.

The Mayfield Heights man, 23, and Garfield Heights man, 31, were students of the school and were expelled for the fight. They were both found to be equal participants in the fight. The incident was forwarded to the prosecutor for review and potential charges.

Theft: Mayfield Road

A Cleveland woman, 33, was cited for theft at Walmart Feb. 25 after she used a packet of taco seasoning to scan in place of several other items at a self-checkout register. Instead of paying full price for the items, she paid 73 cents each. The total value of the theft was $139.

Read more news from the Sun Messenger.

Continue reading here:
Woman blames theft on distraction and partial blindness: Mayfield Heights Police Blotter - cleveland.com

Read More...

First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug – – pharmaphorum

March 6th, 2020 5:46 am

A first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, a technology that allows genes to be manipulated inside the body.

The two companies claim AGN-151587 (EDIT-101) for Leber congenital amaurosis type 10 (LCA10) an inherited form of blindness is the first in vivo CRISPR medicine to be administered to a patient.

CRISPR, is a technology that can edit DNA at precise locations in the human genome, allowing genes to be permanently modified.

AGN-151587 was delivered as an injection under the retina of the eye of a patient at the Casey Eye Institute at Oregon Health & Science University in Portland, US. It will take a few weeks to see if the procedure results in an improvement in vision.

Until now, CRISPR has been used in trials as an ex vivo technique to alter the expression of genes in cells in the lab, which can then be administered to patients as a cell therapy.

The first trial of that approach was conducted in China in 2016 and involved a cell-based therapy for lung cancer, and other studies have followed, including a study of CRISPR Therapeutics and Vertex Pharmas CRISPR ex vivo drug for blood disorders beta thalassaemia and sickle cell disease.

Allergan and Editas say they will test AGN-151587 in a few patients to begin with to see if the procedure is safe, in the phase 1/2 BRILLIANCE trial, and if so over the next few months will enrol 18 children and adults with LCA10, which has no approved treatments.

This dosing is a truly historic event for science, for medicine, and most importantly for people living with this eye disease, said Cynthia Collins, Editas chief executive.

LCA is a group of inherited retinal degenerative disorders that collectively are the most common cause of inherited childhood blindness, with an incidence of two to three per 100,000 live births worldwide.

LCA10 is caused by mutations in the CEP290 gene and accounts for approximately 2030% of all LCA cases.

Dosing into the eye is an easier prospect than systemic delivery via an infusion or pill, but still represents a step forward in the use of CRISPR as an in vivo therapeutic approach.

LCA10 is a good candidate for this type of drug as it cant be treated using other forms of gene therapy that rely on viruses to carry replacement genes, such as Spark Therapeutics Luxturna (voretigene neparvovec), which was approved in 2017 for forms of LCA associated with mutations in the RPE65 gene.

The CEP290 gene is too big to be carried by viral vectors, but using CRISPR its sequence can be edited to restore its normal function, by snipping out a small section.

Allergan licensed rights to Editas drug in 2018 on the strength of preclinical data, paying $15 million to exercise an option first acquired in 2017 for $90 million upfront, part of an alliance for up to five of Editas eye disease programmes.

Editas has also received another $25 million from Allergan under the deal tied to FDA approval to start the BRILLIANCE trial.

Read more:
First patient dosed in trial of Allergan/Editas' CRISPR blindness drug - - pharmaphorum

Read More...

The Mighty Miracles Of Jesus: Healing Bartimaeus Of Blindness – Osprey Observer

March 6th, 2020 5:46 am

During the course of His ministry, Jesus performed more than 40 miracles, including healing the sick, changing the natural elements of nature and even raising people from the dead. A miracle is considered an event that occurs outside the bounds of natural law.

Each month, we will take a closer look at one of His miracles to understand the depth of His love for us. Understanding the miracles of Jesus can change your life, and it all begins with believing through faith.

In the Gospels of Matthew, Mark and Luke, the writers tell of Jesus healing a blind man. Of the many miraculous healings by Christ, it is unusual for the Gospel writers to name the people that were healed, but we can see here that the name of the blind man was revealedBartimaeus. There is much speculation on why Bartimaeus name was mentioned specifically during this miracle.

Biblical historians believe that Bartimaeus miraculous healing and conversion to Christianity was so incredible that it made a great impact on the people who witnessed and heard of it. Bartimaeus healing may have had a large influence and advanced the message of Christ after he was healed. His contribution could have been so significant that it compelled him to be named.

Bartimaeus was a blind man. He was poor, and his main source of income was from begging. Bartimaeus heard that Jesus was in his city, and as Jesus was leaving, Bartimaeus knew that this was his only chance to get healed. He had heard many wonderful things about Jesus, His teachings and His ability to heal the blind.

He went to the street and cried out, Jesus, Son of David, have mercy on me! Then many warned him to be quiet, but he cried out all the more, Son of David, have mercy on me!

If you were stranded on an island, wouldnt you shout from the top of your lungs if you saw a nearby ship? With this same desperation, Bartimaeus cried out to get the attention of Jesus. He thought Jesus didnt hear him at first and he cried out louder, Son of David, have mercy on me!

Now, theres the proof of his faith. He firmly believes that Jesus is the promised Messiah. He called Him the Son of David, a title that is only reserved for the promised and Anointed One.

Jesus said to him, Receive your sight; your faith has healed you, and immediately Bartimaeus received his sight and followed Jesus. When the large crowd of people saw this miracle, as they had known Bartimaeus to be blind for years, they immediately started praising Jesus.

Shouldnt we be like this blind man? Essentially, we have been all blindspiritually blind. We may have chosen the wrong paths and cant seem to find our way out. We may have felt hopeless. But, when we feel the darkness of our choices, we are reminded of our desire to learn of Gods way and to do His will.

This is the same situation where Bartimaeus found himself. This miracle is a reminder that our faith will remove our blindness and let us live fully in the light of Christ.

Read more:
The Mighty Miracles Of Jesus: Healing Bartimaeus Of Blindness - Osprey Observer

Read More...

March declared Workplace Eye Wellness Month by Prevent Blindness in effort to help protect employees’ vision – The Highland County Press

March 6th, 2020 5:46 am

Prevent Blindness, Ohio Affiliate has declared March Workplace Eye Wellness Month.According to theCenters for Disease Control and Prevention (CDC), approximately 2,000 U.S. workers a day sustain a job-related eye injury that requires medical treatment. About one-third of the injuries are treated in hospital emergency departments, and more than 100 of these injuries result in one or more days away from work.

For those who work outside an office setting, Prevent Blindness, Ohio Affiliate warns of common causes for eye injuries and urges everyone to wear the proper eye protection for risks that include:

Flying objects (bits of metal, glass);

Tools;

Particles;

Chemicals;

Harmful radiation; and

Any combination of these or other hazards.

The type of safety eye protection that Prevent Blindness recommends depends on the hazards in the workplace. For areas that have particles, flying objects, or dust, safety glasses with side protection (side shields) should be worn. Goggles should be worn for anyone working with chemicals. And, for those working near hazardous radiation (welding, lasers, or fiber optics) special-purpose safety glasses, goggles, face shields or helmets designed for that task should be worn.

Those who work within an office setting (working with computers and other digital devices) are at higher risk for digital eye strain. According to theAmerican Academy of Ophthalmology, eye strain symptoms include dry eyes, blurry vision, tearing or watery eyes, and headache.The cause ofdigital eye strain is that people blink less when they stare at digital devices. The AAO adds that normally, humans blink around 15 times per minutebut this blink rate can be cut in half when staring at screens or doing other near work activities (like reading).

Prevent Blindness recommends placing a digital screen 20 to 26 inches away from the eyes and slightly below eye level. Also, adjust lighting to lower glare and harsh reflections. More tips may be found at:https://www.preventblindness.org/computers-and-your-eyes.

Recognizing your eye health and safety needs within the workplace, and taking all the necessary steps to protect vision, can help us all to continue to protect healthy eyesight for years to come, said Sherry Williams, President & CEO of the Ohio Affiliate of Prevent Blindness.

The Prevent Blindness Committee of the Ohio Safety Congress will be presenting four eye health and safety educational workshops March 12 at its annual conference at the Columbus Convention Center. Morethan8,000representatives from Ohio businesses and government are expected to attend the Safety Congress which is thelargest and longest-running regional occupational safety, healthandworkers compensation eventin the United States.

For more information about workplace eye health, please call the Ohio Affiliate of Prevent Blindness,at 800-301-2020 or visithttps://www.preventblindness.org/eye-safety-work.

Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight.Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research.These services are made possible through the generous support of the American public.Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America.For more information, or to contribute to the sight-saving fund, call 1-800-331-2020.Visit Prevent Blindness on the web atpbohio.org,Facebook atfacebook.com/pbohio or Twitter attwitter.com/PB_Ohio.

The rest is here:
March declared Workplace Eye Wellness Month by Prevent Blindness in effort to help protect employees' vision - The Highland County Press

Read More...

‘The Incredible Dr. Pol’: Dr. Pol’s Color-Blindness and How It Affects His Work – Showbiz Cheat Sheet

March 6th, 2020 5:46 am

NatGeo WILDs The Incredible Dr. Pol really is a remarkable vet. His show has a strong following because of his can-do, energetic attitude. Not much stumps the doc.

One of the very few limitations Dr. Pol has, he admits, is his color-blindness.

Arriving to the United States in 1961, Dr. Pol, like so many others, could not yet speak English. He met that challenge head-on. The 77-year-old just made himself learn it. Having his American wife, Diane, by his side made learning it even easier.

In his memoir, Never Turn Your Back on an Angus Cow, Dr. Pol described his first time on an airplane as he left the Netherlands to come to America.

Like most of my classmates, that was my first time on an airplane. While for many people the concept of going to live in America might be exciting or scary, the Dutch are pretty stoic; we tend to accept things as they happen without showing a great deal of emotion.

Dr. Pol took to his new homeland quickly and before he knew it, was speaking the local language just as swiftly.

It took eighteen hours to fly from Amsterdam to Detroit. We arrived in the middle of August. I spoke a passable British English. We were told that within three months, we would be dreaming in English, but for me, it was only two weeks.

Thirty years into his private practice in Weidman, Michigan, fame came calling at Dr. Pols doorstep.

His son, Charles, had been working in L.A., when he had the idea of developing a reality show around his veterinarian dad. Dr. Pol couldnt imagine who on earth would want to watch him stick his arm into cow after cow, but he went along with it.

Its an incredibly adaptable person -especially someone whos already been doing things a certain way for 30 years who will have an open mind to allowing cameras and chaos into their everyday lives.

I agreed to let his camera crew follow our staff for a few days, still wondering if anyone was going to watch. It turned out Diane and I raised a smart son, Dr. Pol writes in his book.

As stated, Dr. Pol is color blind, and particularly has trouble with the colors green and brown. He hasnt allowed this to slow him down in his work as it just requires confirmation from whoevers around him to help him with anything he might have trouble reading the color on.

He writes about this challenge, I have always had a hard time learning from books. Show me how something is done and Ill remember it. Show me a surgery one time and I can do it the next time. What made it even more difficult for me was the fact that Im color-blind. That made pathology especially hard. I couldnt make the diagnoses that were based on the color of the tissue.

In the clinic, then, the doc has one of the staff help him out with microscope slides.

. . . we now have a very good microscope with a camera on it, he wrote. But for me, there are things I cant do under a microscope because Im color-blind I have to get the slide ready and ask someone else to look at it for me.

Read more: The Incredible Dr. Pol: The Countries His Show Is Popular In May Surprise You

Here is the original post:
'The Incredible Dr. Pol': Dr. Pol's Color-Blindness and How It Affects His Work - Showbiz Cheat Sheet

Read More...

Medical student’s epic journey to help fight preventable blindness – Hereford Times

March 6th, 2020 5:46 am

A HEREFORD medical student will be travelling 15,000 km on his motorcycle to help save the sight of people living in areas hardest hit by preventable blindness.

Hugo Jobst, who is studying at the University of St Andrews, is undertaking an eight month expedition on his motorcycle throughout India and Nepal to train midwives and nurses with the Arclight Ophthalmoscope, a life-changing diagnostic device.

Beginning in November 2020, Hugo will visit 35 institutions, and train over 1,000 midwives and nurses.

Developed at St Andrews in collaboration with Dr Andrew Blaikie, the Arclight is a solar powered diagnostic device used to examine the eyes and ears, accurately detecting diseases that cause blindness and deafness. Importantly, due to its durability and low production costs, it is designed to be accessible to low-resource areas.

According to The World Health Organisation, there are 250 million people living without sight, 40 percent of these in India alone. Of these people, 80 percent can be cured, but early detection is vital.

Hugo is being supported in his sight-saving quest by Hereford's BBR Optometry. Practice manager Daniel Read said: The fight against preventable blindness is an ongoing challenge. The people most affected are often the furthest away from appropriate care, but by travelling to rural areas and training and equipping workers, Hugo will be giving many more children the best chance at a fair start to life.

We wish Hugo all the best and cant wait to follow his journey.

Click here to read more about Hugos adventure and find out how to donate to this incredible cause here

Excerpt from:
Medical student's epic journey to help fight preventable blindness - Hereford Times

Read More...

Tackling inherited blindness, Editas and Allergan use CRISPR for the first time in the human body – Endpoints News

March 6th, 2020 5:46 am

Ebola. Sickle cell disease. Spinal muscular atrophy. Cystic fibrosis.

Everyone agrees the void is a problem, but theres little consensus on how to tackle it and theres no panacea to speak of.

Behind each disease was a medical breakthrough that Francis Collins highlighted at the congressional hearing on the presidents 2021 NIH budget request, a yearly opportunity to update lawmakers on his agencys progress and priorities. Thanks to three decades of research that dates in part back to his own NIH-backed work at the University of Michigan, for instance, the US has ushered in its first triple therapy for cystic fibrosis last year.

These are dramatic times for NIH research, the director concluded.

Bolstering the burst in new scientific discovery and therapeutic development has been an impressive growth in NIH funding. President Donald Trump may be proposing to cut its budget down 7% next year, but over the past five years it has increased by $11.6 billion, or 39%, according to Rep Rosa DeLauro, chair of the House Appropriations subcommittee on Labor, Health & Human Services and Education. That has translated to a $8 billion boost to the total amount of grants awarded between 2014 and 2019, per NIH disclosure.

The steady increases you have provided have brought new life to biomedical research and built the foundation for us to take on new and unexpected challenges, Collins said, challenges like the one thats on everyones mind right now: the global coronavirus outbreak.

What does this new life look like on the ground? Endpoints News spoke to researchers, administrators and advocates, who pointed to different metrics that either measure output or the environment that scientists find themselves working in. The conversations suggest while the increases which followed years of stagnation did pump more resources into translatioal research, they didnt quite solve the challenges basic science still faces.

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Read the original:
Tackling inherited blindness, Editas and Allergan use CRISPR for the first time in the human body - Endpoints News

Read More...

International Team Delivers Breakthrough for Leading Cause of Blindness – Business News Wales

March 6th, 2020 5:46 am

Researchers have identified a new protein linked to age-related macular degeneration (AMD) that could offer new hope for the diagnosis and treatment of the disease, which affects more than 1.5 million people in the UK alone.

The research team, made up of scientists from Cardiff University, Queen Mary University of London, the University of Manchester, and Radboud University Medical Center, Nijmegen, found significantly higher levels of a protein called factor H-related protein 4 (FHR-4) in the blood of AMD patients.

Further investigation, using eye tissue donated for medical research, showed the presence of the FHR-4 protein within the macula the specific region of the eye affected by the disease.

The results of the study, published in Nature Communications, open up new routes for the early diagnosis by measuring FHR-4 levels in the blood, and suggests therapies targeting this protein could provide promising future treatment options for the disease.

Professor Paul Morgan, an expert in complement biology at Cardiff University and leader in the development of the antibodies and assays that underpinned this work, said:

The collaboration between experts in complement biology, eye disease and genetics across Europe has enabled the accumulation of a robust body of evidence that genetically dictated FHR-4 levels in plasma are an important predictor of risk of developing AMD.

The unique antibodies and assays we have developed have potential not only for contributing to risk prediction but also to new ways of treating this common and devastating disease.

FHR-4 regulates the complement system, part of the immune system, which plays a critical role in inflammation and the bodys defence against infection.

Previous studies have linked the complement system to AMD, showing that genetically-inherited faults in key complement proteins are strong risk factors for the condition.

In this study, the researchers used a genetic technique known as a genome-wide association study to identify specific changes in the genome related to the increased levels of FHR-4 found in AMD patients.

They found higher blood FHR-4 levels were associated with changes to genes that code for proteins belonging to the factor H family, which clustered together within a specific region of the genome. The identified genetic changes also overlapped with genetic variants first found to increase the risk of AMD over 20 years ago.

Together, the findings suggest that inherited genetic changes can lead to higher blood FHR-4 levels, which result in uncontrolled activation of the complement system within the eye and drive disease.

Blood levels of FHR4 were measured in 484 patients and 522 age-matched control samples using two independent, established collections of AMD patient data.

There are two main types of AMD .wet AMD and dry AMD. While some treatment options exist for wet AMD, there is currently no available treatment for dry AMD.

The authors said the study represented a step change in their understanding of the involvement of complement activation in AMD.

Professor Simon Clark, a specialist in the regulation of the complement system in health and disease at the University of Manchester, said:

Up until now, the role played by FHR proteins in disease has only ever been inferred.

But now we show a direct link and, more excitingly, become a tangible step closer to identifying a group of potential therapeutic targets to treat this debilitating disease.

Continue reading here:
International Team Delivers Breakthrough for Leading Cause of Blindness - Business News Wales

Read More...

Stem cell therapy used to treat severe cases – The Star Online

March 6th, 2020 5:45 am

BEIJING: Chinese researchers are studying the use of stem cell technology in the treatment of people critically ill with the novel coronavirus disease (Covid-19), according to the Science and Technology Daily.

Four Covid-19 patients who received stem cell treatment while in a serious condition have been discharged from hospital after recovery, and the clinical trial of the therapy will be further expanded, Vice-Minister of Science and Technology Xu Nanping was quoted by the paper as saying.

Stem cells can self-renew or multiply while maintaining the potential to develop into other types of cells.

They can become cells of the blood, heart, lungs or other body parts.

Stem cells also have a strong secretory function, promoting the formation of new blood vessels, cell proliferation and differentiation and inhibiting inflammatory response, experts say.

Stem cell therapy has been used in the treatment of some infectious diseases and complications. For instance, it has been tried in treating H7N9 avian flu and showed good results.

According to the Ministry of Science and Technology, the Chinese Academy of Sciences has developed a new stem cell drug, CAStem, which has shown promising results in animal experiments.

The research team has applied for urgent assessment by the National Medical Products Administration.

Approvals by the ethics committee, and clinical observation and evaluation are in progress.

A research team from the fifth medical centre of the Chinese PLA General Hospital is cooperating with hospitals and institutions in Wuhan, the epicentre of the epidemic, and North Chinas Tianjin municipality to conduct clinical research on the safety and effectiveness of mesenchymal stem cell therapy in treating Covid-19 patients. China Daily/ANN

Go here to read the rest:
Stem cell therapy used to treat severe cases - The Star Online

Read More...

Everything you need to know about Myeloma – IOL

March 6th, 2020 5:45 am

By Partnered Content Mar 2, 2020

Share this article:

Most of you reading this would have probably never heard of such a disease. My hope is, after taking time to read this, that you will know what myeloma is and have a better understanding of bone marrow cancer in general.

So, lets get started!

Your bone marrow is the factory where all your blood cells are made. This includes red blood cells (they carry the oxygen in your blood), white blood cells (your bodys defence against infections) and platelets (small fragments that prevent and stop bleeding).

The production of these cells by the bone marrow is very well controlled by your body, both in terms of the amount and the type of cells produced. If you have an infection, for instance, your body tells the stem cells in your bone marrow to make more white blood cells to help fight the infection. In such instances, an immature, baby cell gets produced in your bone marrow which then needs to go through various stages of growth and development to become a mature white blood cell. It is then released from the bone marrow into your bloodstream to go and do the job it was destined for, to fight the infection.

This process usually runs quite smoothly, but things can, unfortunately go horribly wrong. Sometimes your body makes a mistake in the production of a white blood cell, almost like a programming error which occurs in the DNA (blueprint) of the cell. It often recognizes its mistake and corrects it, but occasionally this abnormal cell has the ability to hide from your bodys defences, doesnt listen to your bodys commands anymore and can start to increase in number without anything controlling it. This causes a variety of problems and is then called cancer.

Depending on the type of white blood cell and where in its development the programming error occurs, a person can either develop a type of bone marrow cancer (usually leukaemia or myeloma) or lymphoma (glandular cancer), which is also a type of cancer that develops from an abnormal white blood cell.

That brings us to myeloma (also called multiple myeloma or plasma cell myeloma). Myeloma is a type of bone marrow cancer that develops when a programming error occurs in the development of a specific type of white blood cell, called a plasma cell. To understand myeloma better, it is important to understand what role a plasma cell plays under normal circumstances.

They are indeed an integral part of your bodys immune system. Any infection that you may develop gets recognized by your plasma cells. They respond by rapidly producing small proteins called antibodies, which are almost like homing missiles, programmed to go and destroy only that specific virus or bacteria that is making you ill.

After an infection, some of the antibodies remain in your bloodstream and if you are exposed to that exact virus or bacteria again, they are ready to attack immediately, thereby limiting the infection. This is the rationale behind childhood vaccination; to stimulate the production of antibodies which patrol your bloodstream and protect you when you get exposed to infections like measles, polio and many others.

If these plasma cells become cancerous however, they rapidly increase in number, taking over the bone marrow and producing a massive amount of an abnormal antibody which can cause a whole array of problems. This increase in antibody levels in the bloodstream can be measured with a blood test and is also used to monitor the response to treatment.. What are thesymptoms of myeloma?

The abnormal plasma cells in the bone marrow overwhelms the normal bone marrow which most commonly leads to an inability to produce enough red blood cells. This is called anaemia. Symptoms of anaemia are related to the bodys inability to carry sufficient oxygen to your organs and include worsening fatigue, shortness of breath and dizziness.

The abnormal plasma cells also have the ability to weaken your bones. This can either be a generalized loss of bone strength (called osteoporosis), or it can lead to numerous holes being eaten in your bones. This can be seen on an X-Ray or other types of scans. It often results in significant bone pain or even worse, severe fractures with minimal- or even no trauma at all.

Bones are rich in calcium, and if they are being eaten away, their calcium content is released into the bloodstream causing an elevated blood calcium level. This can lead to dehydration, kidney failure and numerous other symptoms.

As mentioned before, the plasma cells in the bone marrow releases a massive amount of abnormal antibodies into the bloodstream. They can clog up your kidneys and cause significant- and often irreversible kidney failure. This can seriously complicate the management of the disease.

These are by far the most common features of myeloma:

Anaemia, bone lesions or fractures, hypercalcaemia and kidney failure.There are numerous other symptoms which can occur, albeit less common.

Is myeloma treatable?

Myeloma is indeed a treatable condition, but there are a couple of important treatment principles to understand.

For most people, myeloma is not a curable disease. It can, however, be carefully managed and the aim of treatment is to provide a good quality of life for as many years as possible. No patients disease is the same and where we sometimes have patients with myeloma living in excess of ten years after being diagnosed, other patients are unfortunately less fortunate and have a form of the disease that is resistant to treatment which can take its toll after only a couple of months.

We perform DNA-tests on the cancer cells and look at various other blood results in an attempt to identify those patients with high-risk disease, who potentially need more intense treatment than others.

The goal of treatment is to destroy as many abnormal plasma cells in the bone marrow as possible. This leads to recovery of the normal bone marrow and minimises the risk of any further complications, giving the body a chance to recover from any complications caused prior to treatment.

For many decades, the backbone of the treatment for myeloma was a combination of two different type of drugs: Chemotherapy and high dosages of cortisone. This is usually quite well tolerated.

The last couple of years, however, have seen an explosion of newer therapies for the treatment of myeloma. This started years ago with the discovery that Thalidomide, was extremely effective for the treatment of myeloma. Soon, more of these so-called novel therapies were developed, leading to a significant increase in the survival of patients who have access to these drugs.

The latest and most impressive of these treatments are certainly the development of monoclonal antibodies and CAR-T cells, both of which are extremely effective even in high risk or resistant myeloma. There is so much excitement about all the newer therapies, but access remains a challenge in theSouth African market.

A strong collaborative effort is required amongst pharmaceutical companies, government and medical schemes, to improve the current access of newer drugs. Nevertheless, some of these drugs have been around for many years and the costs have come down considerably, making it accessible to more people.

The initial treatment of myeloma generally consists of varying combinations of these drugs depending on the patients age, physical condition and of course, the available funding.

We usually use 3 different drugs in combination (a so-called triplet regimen) which has been proven to be very effective. Once the treatment is started, we take blood regularly to monitor the abnormal antibody levels in the blood which, as mentioned earlier, is a surrogate indicator of the number of cancer cells remaining in the bone marrow.

If we dont see a significant downward trend, the disease is likely resistant to that specific treatment combination and treatment should be adjusted accordingly. However, if the antibody levels come down significantly, we are on the right track and can continue with the same treatment until an optimal response is obtained or the development of side-effects forces us to make an adjustment.

After 4-6 months of treatment, the hope is to see no sign of any abnormal antibodies or cancer cells anymore (we call this a remission), or at least a dramatic reduction. We do however know that although we sometimes dont pick up any sign of residual disease, it is merely because the available tests are not sensitive enough. There will always be some cancer cells that remain.

As a general principle, however, the less residual disease, the longer it usually takes before it causes problems again. Because of this, we usually treat younger patients more aggressively in an attempt to obtain a deeper remission. The biggest difference in younger patients is the use of an autologous stem cell transplant as a 2nd phase of treatment to try and obtain or deepen a remission.

We harvest the patients bone marrow stem cells and keep them frozen until needed. We then administer a single high dose chemotherapy which destroys many of the remaining cancer cells, but in the process, it also destroys the normal bone marrow, without which you cannot survive. The patients stem cells are then thawed and given back to them like a blood transfusion.

After about two weeks of close monitoring in the hospital, the stem cells start to function and the patient subsequently has his/her own bone marrow back, hopefully with significantly less myeloma. The age cut-off for such a procedure is arbitrary because it largely depends on the physical condition of the patient. Most people in South Africa, however, use the age of 70 as a cut off, sometimes a bit older if the patient is in exceptional condition for his/her age.

The median age of people diagnosed with myeloma worldwide is about 70 years. The available data, however, suggests that the median age in South Africa is considerably younger, somewhere around the age of 60 years. Due to this, as well as the problems with drug availability in South Africa, we often rely quite heavily on stem cell transplantation as an important part of treatment. If enough stem cells are harvested and cryopreserved, such a transplant can be repeated on numerous occasions to improve disease control.

After a transplant, as well as for those patients who are not candidates for a transplant, a form of low-intensity maintenance therapy is often started as the next phase of treatment in an attempt to keep the disease under control for as long as possible. This duration varies considerably. We hope for a couple of years, but it is unfortunately sometimes just a couple of months before the disease worsens, after which more intense treatment needs to be restarted again and the above cycle repeats itself. The remission duration gives us a good indication regarding the nature and prognosis of the disease.

There is so much more detail about myeloma to share, but the bottom line is this: Although myeloma is not a curable cancer and can lead to devastating complications, there is good treatment available which can help many patients enjoy a good quality of life for many years.

It is important to diagnose myeloma early, so if you have some of the symptoms mentioned earlier, please contact your General Practitioner for further investigation. If any abnormalities are detected, your GP can refer you to aClinical Haematologist, who specialises in bone marrow cancers and are best equipped to treat your myeloma.

We are all very excited about the future of myeloma treatment and hope that the treating physicians, pharmaceutical companies and government can take hands to ensure proper treatment for all the people in South Africa who suffer from this disease.

This article was compiled by Dr. Hannes Koornhof (Chairman of SACHAS)MBChB, FCP (SA), Dip HIV Man (SA), Cert Clin Haematology (SA) PhysSponsored by JANSSEN PHARMACEUTICA(PTY) LTD/(EDMS) BPK. (Reg. No./Regnr. 1980/011122/07); No 2, Medical Road, Halfway House, Midrand, 1685.www.janssen.com.

Medical Info Line: 0860 11 11 17. EM-27036

Read the original:
Everything you need to know about Myeloma - IOL

Read More...

Cape Town Cycle Heroes Raising Funds for 5-Year-Old with Rare Genetic Condition – SAPeople News

March 6th, 2020 5:45 am

Aaron Lipschitz (5) from Sea Point, Cape Town

Of the few known cases worldwide, Aaron is the only child who is unable to tolerate any food without becoming very ill. The only nutrition he has been able to cope with is a hypoallergenic formula called Similac Alimentum. He is currently fed via a MIC-KEY feeding port in his stomach.

As there is currently no cure for Aarons condition, the only way for him to overcome his recurrent infections and survive this condition, was to have a bone marrow transplant.

To help cover the costs of finding an international bone marrow donor, as well as assist his family with his ongoing medical expenses, acampaignwas created on donations based crowdfunding platform, BackaBuddy.

Over the course of two years, the BackaBuddy campaign has raised over R1 629 017.18 to support Aaron with contributions from over 978 donors both locally and abroad.

Finally in August 2018, Aarons family got the call they had been waiting for.

With the support ofThe South African Bone Marrow Registry, a 100% bone marrow match was found for Aaron overseas. At only 3 years old, Aaron underwent chemotherapy to destroy his current defective immune system before it was replaced with the donors bone marrow.

The risky procedure was met with complications when Aaron developed a very rare reaction to the new bone marrow, called a Cytokine Storm, which landed him in Red Cross ICU for a month. The fact that he was able to survive the transplant is a miracle, says Aarons mom, Taryn.

Aaron is a fighter in the true sense of the word. His doctors were trying to prepare us for the worst and I told them to wait and seeAaron survived against all odds. He has the most incredible zest for life and thirst for knowledge. says Taryn.

WATCH: Short documentary video on Aaron when he was 4 years old:

Since the bone marrow transplant, Aaron seems to be getting fewer infections but unfortunately, his immune system has not reconstituted as well or as quickly as doctors would have liked. To boost his immune system, he needs to have weekly immunoglobulin treatment.

When the transplant had no significant change on Aarons inability to tolerate food, his medical team decided to do a whole-genome sequencing to determine the root of the problem. They soon discovered a second rare genetic variant known as Fox P3, the gene responsible for the overall regulation of a persons immune system, which may be contributing to the food allergy component of Aarons condition.

Doctors also believe this second diagnosis may also explain why Aarons immune system responded so slowly to his bone marrow transplant.

Despite surviving such a tough procedure, Aaron still has a very long and challenging journey ahead. Whenever we feel that we are getting close to the summit of this mountain, the mountain seems to become higher. All we can do is keep our heads down and keep putting one foot in front of the other. says Taryn.

On the 8th of March, nine Capetonians lead by Rebettzin Sara Wineberg, will take on the Cape Town Cycle Tour, cycling a distance of 109 km to raise fundsfor Aarons ongoing medical expenses.

Aaron currently survives on a hypoallergenic formula administered 3-4 times a day via a MIC-KEY feeding tube in his stomach.

He still requires weekly immunoglobulin infusions where a tiny needle is inserted under the skin in his stomach to administer the infusion.

Aaron is in occupational therapy, physiotherapy and play therapy to help support him and allow him to lead the most normal life possible.

Rebbetzin Sara Wineberg from Sea Point, Cape Town, is excited to take on the Cape Town Cycle Tour for the second time, this year

I met Aaron when he was in the ICU just after his bone marrow transplant, things were not looking good and I came together with a group of women to pray for him. I have witnessed the miracle that is Aaron, he is our miracle and I want to help see more miracles come through for him and his family! says Sara.

Taking on the Cycle Tour for the first time, high schoolers from Cape Town Torah High School, Yehuda Hecht (16), Nissim Brett (15) and Joseph Meltzer (15) are enthusiastic to support Aarons treatment and make a positive difference. They will also be joined by Rabbi Pinni Hecht, Elenor Miller, Ronit Netter, Terry Deats and Aliyah Kaimowitz.

We are so fortunate that along this very challenging trail we have many angels helping us carry this load. Its been a relief to restart Aarons BackaBuddy campaign. Aaron still has a very long and challenging journey ahead. The years of high medical costs have really taken a financial toll on our family. says Taryn

Ahead of the Cycle Tour this Sunday, the Riding for Aaron campaign has already raised a total of R94 699.18 towards the fundraising target of R120 000 with contributions from 128 donors.

The Lipschitz family would like to encourage all South Africans, to register as bone marrow donors to give children like Aaron a second chance at life.

To date, theSABMRhas helped save the lives of nearly 500 patients with life-threatening blood disorders by matching them with healthy, unrelated bone marrow donors from South Africa and the rest of the world.

According to SABMR, Sustainability Portfolio Manager, Kamiel Singh, there are currently only 74 000 donors registered on the site to cater to over 57 million South Africans.

We are urging people to go onto theSABMR websiteto register as a bone marrow/stem cell donor. The process is as simple as making a phone call, filling out a form and having a mouth swab taken. You could save Aaron or another person waiting for their miracle. says Taryn

Register to become a bone marrow donor with the SABMR[click here]

View post:
Cape Town Cycle Heroes Raising Funds for 5-Year-Old with Rare Genetic Condition - SAPeople News

Read More...

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study – BMC Blogs…

March 6th, 2020 5:45 am

Postmenopausal osteoporosis is the most common bone disease. It is characterized by reduced bone mass and microscopic changes in the architecture resulting in impaired strength of bones, with consequent increased susceptibility to fracture, which results in high medical expenditures and substantial morbidity with a decrease in quality of life [1, 2]. The bone mineral density (BMD) reduces with age in the entire population, and women are particularly at higher risk since they rapidly lose bone in the peri- and post- menopausal periods [2]. Age, sex, family history, low baseline weight, weight loss, and alcohol use in women, and smoking in men are generally associated with low BMD [2]. Owing to an increasing life expectancy, the number of patients has been progressively increasing worldwide [3]. One of the most debilitating complications of osteoporosis is hip fracture, which has an estimated probability of 3.5% in men and 14.6% in women around the age of 50years old. Approximately 2050% patients with hip fracture suffer from a decreased quality of life, depression, loss of self-esteem, and social isolation, which leads to the drastic elevation of one-year mortality rate, up to 1460% [4,5,6,7]. Vertebral fractures are extremely common complications of osteoporosis and often asymptomatic. However, multiple vertebral thoracic fractures may induce restrictive lung disease and secondary heart problems. Lumbar fractures may cause gastrointestinal complaints, back pain (both, acute and chronic), depression, and positional restriction, resulting in increased mortality [7, 8]. In view of these numerous complications, the main objective of treating postmenopausal osteoporosis is the prevention of future fractures.

The two types of treatment options for osteoporosis include anti-resorptive and anabolic agents. Anti-resorptive drugs include bisphosphonates (e.g. alendronate, minodronate (MIN), etidronate, risedronate, pamidronate, and zoledronate), selective estrogen-receptor modulators (raloxifene and bazedoxifene), active vitamin D3 derivatives (alfacalcidol and eldecalcitol), a fully human monoclonal antibody to receptor activator of nuclear factor -B ligand (RANKL; denosumab), and thyroid hormone (calcitonin). Anabolic agents include parathyroid hormone (teriparatide), parathyroid-related peptide synthetic analogs (abaloparatide), and a sclerostin inhibitor (romosozumab) [9]. Among these treatment options, bisphosphonates are the most widely used all over the world. MIN is a third-generation bisphosphonate and the strongest inhibitor of bone resorption among the currently available oral bisphosphonates. In terms of bone resorption inhibition, MIN is 1000-fold more effective than etidronate and 10100-fold more effective than alendronate [10]. Large randomized, placebo-controlled, double-blind clinical trials revealed a significant increase in bone mineral density (BMD) of both, the lumbar spine and femoral neck over 3years of MIN therapy and a risk reduction in vertebral fractures in Japanese women with postmenopausal osteoporosis [11]. Therefore, MIN continues to be one of the most widely used bisphosphonates in Japan.

Denosumab is a fully human monoclonal anti-RANKL IgG2 antibody that inhibits the binding of RANKL to its receptor on osteoclasts, thereby decreasing the bone-resorption activity of mature osteoclasts [12]. In the phase 3 Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6Months (FREEDOM) trial, denosumab treatment significantly reduces the incidence of new vertebral, nonvertebral, and hip fractures compared with placebo treatment [13]. Furthermore, in the FREEDOM Extension trial, 10-year treatment with denosumab increases the BMD of patients progressively with a significantly lower incidence of fracture [14]. In Japan, denosumab is currently one of the first treatment options, as evidenced by the report that sales of denosumab exceed that of each bisphosphonate [15]. Lyu et al. performed a meta-analysis of 10 eligible trials including 5361 participants comparing denosumab and bisphosphonates [16]. Denosumab increases BMD more than bisphosphonates at the lumbar spine, total hip, and femoral neck. Furthermore, one study showed that denosumab has a lower osteoporotic fracture incidence than alendronate at 24months (risk ratio, 0.51; 95% confidence interval, 0.27 to 0.97) [17]. Based on this clinical evidence, both denosumab and bisphosphonates are widely prescribed for osteoporosis in Japan. However, since denosumab is more easily administered by two annual injections with less complication, which may possibly increase the compliance rate, it appears to be the better choice between the two drugs. Therefore, we assumed that it can be considered as a reasonable treatment option to switch from bisphosphonates to denosumab in the clinical setting. However, only a few studies have reported the efficacy of switching from bisphosphonates to denosumab; therefore, the evidence level remains low.

In view of these findings, we advised patients treated with MIN for more than 2years to switch to denosumab if they agreed after the detailed explanation of each drug from treating physicians. In this study, we aimed to retrospectively evaluate the treatment effects of patients who switched to denosumab and compared with those of patients who continued MIN treatment.

See the original post:
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study - BMC Blogs...

Read More...

CytoDyn Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to…

March 6th, 2020 5:45 am

VANCOUVER, Washington, March 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive data for its mTNBC and MBC patients.

Metastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has a poor prognosis. In addition, metastatic breast cancer (MBC) is breast cancer that has spread beyond the breast and lymph nodes to other organs in the body (typically the bones, liver, lungs, or brain). Both types of cancer pose significant challenges for patients due to their aggressiveness and limited treatment options. An integral part of CytoDyns mission and purpose is to provide effective therapeutic solutions to these patients. Results of the first five patients are as follows:

Patient #1: Enrolled in mTNBC Phase 1b/2 - Injected on 9/27/2019. CTC (circulating tumor cells) dropped to zero in two weeks on 10/11/2019. Total CTC and EMT (Epithelial Mesenchymal Transition in Tumor Metastasis) dropped to zero after about one month of treatment with leronlimab (once-a-week 350 mg dose). Results from the patients earlier CT scan indicated a more than 25% tumor shrinkage within the first few weeks of treatment with leronlimab. Most importantly, after more than five months of treatment with leronlimab and Carboplatin, the patient not only has zero CTC and zero EMT, but also zero detectible CAML (cancer-associated microphages like cells).

Patient #2: Enrolled in single IND. Patient is MBC with HER2+ stage 4 metastasis to lung, liver, and brain. Patients radiologist cancelled 2nd round of treatment due to leronlimabs effect on shrinking the largest tumor in the brain by 56% and other lesions being stable. Leronlimab has and continues to be the only treatment in place for brain metastasis after radiation was administered to this patient in July 2019. Four and one-half months after successful radiation treatment, the patient received her first dose of leronlimab (700 mg) and no other drugs to treat the brain metastasis. The 56% shrinkage in the brain lesions occurred after only two once-weekly injections of leronlimab. After 10 weeks of treatment with leronlimab, this patients CTC and EMT results were all zeros (results reported on 2/12/2020). The patients CT scan in mid-February was reported as stable.

Patient #3: Enrolled on 1/3/2020. This patients CAML counts decreased from 45 to 30. CTC+EMT are stable and there has been no change in the total number. Despite positive results, this patient stopped treatment due to complications with her implanted port, which was unrelated to leronlimab.

Patient #4: Enrolled on 1/7/2020. This patients total CTC dropped by 75% in the first two weeks of treatment with leronlimab. After almost five weeks of treatment, the CTC remained at zero.

Patient #5: Enrolled on 2/4/2020. This patient has traveled from England to receive leronlimab. Initial response from treatment indicated tumor shrinkage and, importantly, CTC dropped to zero after three weeks of leronlimab treatment.

Patients #6 and #7: Enrolled and waiting for the first results post-baseline results.

Patients #8 through #10: Will be injected in early March.

Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, Patients continue to be actively enrolled in this trial based on the expression of CCR5 on lymphocytes and macrophages in the tumor microenvironment. The proposed mechanism of action (MOA) consisting of inhibition of Tregs and repolarization of macrophages has demonstrated a predictable, sustained response that has reduced the size of primary and metastatic tumors and reduced circulating tumor cells in all patients tested so far.

Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, added, These findings are solidifying our belief of the four mechanism of actions (MOA) for leronlimab in the treatment of cancer, as previously verified through preclinical animal studies and in published papers. These MOAs indicate that leronlimab may potentially stop metastasis in many types of solid tumor cancers, trigger the bodys immune response system to destroy the cancer tumor and perhaps more. This could represent the beginning of the transformation of CytoDyn from a potential leader in HIV therapy to providing potentially a new innovative treatment opportunity to patients with various forms of cancer and potentially NASH, GvHD, MS, and perhaps many more indications. With the possibility of our first approval in HIV late this year, we could have over 30 label expansion opportunities post-HIV approval.

Story continues

About Triple-Negative Breast CancerTriple-negative breast cancer (TNBC) is a type of breast cancer characterized by the absence of the three most common types of receptors in the cancer tumor known to fuel most breast cancer growthestrogen receptors (ER), progesterone receptors (PR) and the hormone epidermal growth factor receptor 2 (HER-2) gene. TNBC cancer occurs in about 10 to 20 percent of diagnosed breast cancers and can be more aggressive and more likely to spread and recur. Since the triple-negative tumor cells lack these receptors, common treatments for breast cancer such as hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.

About Leronlimab (PRO 140)The U.S. Food and Drug Administration (FDA) have granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is therefore conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additionalclinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Companys cash position, (ii)the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv)the Companys ability to enter into partnership or licensing arrangements with third parties, (v)the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Companys ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Companys clinical trials, (viii)the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTS

Investors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

Originally posted here:
CytoDyn Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to...

Read More...

Vir Biotechnology and Alnylam Join the Fight Against COVID-19 – Motley Fool

March 6th, 2020 5:44 am

Yet another biotech has joined the fray against the novel coronavirus: Alnylam Pharmaceuticals (NASDAQ:ALNY) andVir Biotechnology (NASDAQ:VIR) on Wednesday announced they were expanding their ongoing collaboration to include an attempt to develop RNA interference (RNAi) treatments for SARS-CoV-2.

According to the American Society for Microbiology, coronaviruses are everywhere. They are the second-leading cause of the common cold, after rhinoviruses. In an article on the society's website, Dr. Rodney Rhode wrote, "Coronaviruses ... mutate and change at a high rate, which can create havoc for both diagnostic detection as well as therapy (and vaccine) regimens."

Image source: Getty Images

The two companies have been collaborating since the 2017 founding of Vir, which specializes in using immunology to fight and prevent infectious diseases. Vir CEO George Scangos was the CEO ofBiogenbefore he took control of the start-up.

"Given the scope and speed of the COVID-19 outbreak," Scangos said, "Vir is seeking multiple approaches that combine our expertise in infectious disease with that of current and new partners to respond rapidly. Alnylam has been an excellent partner, and our complementary capabilities made this a compelling opportunity..."

As Alnylam CEO John Maraganore said, "We believe RNAi therapeutics represent a promising approach for targeting coronaviruses, like SARS-CoV-2. As the leader in RNAi therapeutics, we at Alnylam are committed to doing our part in joining other biopharmaceutical companies, like Vir, to address this emerging outbreak."

Vir will lead all development and commercialization of any selected drug molecules. Alnylam retains the option to share in the profits and losses associated with the effort. Shares of Vir were up 14% in early trading Wednesday, while Alnylam was up 3%.

{%sfr%)

Read more from the original source:
Vir Biotechnology and Alnylam Join the Fight Against COVID-19 - Motley Fool

Read More...

Page 651«..1020..650651652653..660670..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick